Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Companies
Shield Therapeutics is to slash its workforce and is considering a possible sale in the wake of a failed Phase III study for its only marketed product, Ferracru, that should have given it access to the US market.
The US biotech expects to finally get its PARP inhibitor for ovarian cancer onto the European market in the next few months to compete with rivals AstraZeneca and Tesaro after the CHMP "communicated a positive trend vote" ahead of an opinion being issued next month.
Several Indian startups - many with overseas links - appear to be taking a shot at developing, among others, novel treatments targeting multi-drug resistant infections, biobetters and personalized cell based therapy. Funding, though, hasn’t been easy, according to one biopharma advisory firm.
Appointments: Changes At Hikma, Bluebird Bio, Celgene, Alkermes, Cell Medica, Editas Medicine, Futura Medical, Corline Biomedical And Horizon Discovery
Pharma and biotech appointments this week include a new CEO at Hikma and an interim-CEO at Horizon Discovery, a Chief Commercial Officer for bluebird bio, and new board directors at Celgene, Alkermes, Editas Medicine, and Futura Medical.
RespireRx president & CEO James Manuso explained to Scrip during the 2018 Biotech Showcase how the company is repurposing an existing drug to tackle the problem of sleep apnea.
Acquisition reflects that regulatory-grade real-world evidence will play increasing role in drug discovery, development, commercialization and reimbursement.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.